Ketryx announced today that DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), has selected Ketryx to accelerate the ...
Truist Financial analyst David S Macdonald reiterated a Buy rating on Radnet (RDNT – Research Report) today and set a price target of $94.00. The company’s shares closed last Wednesday at $82.49.